Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WGc0201 in Chronic Hepatitis B
NCT07051187Phase 1Recruiting
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of WGc-0201 in Chronic Hepatitis B (CHB). Primary endpoint: Adverse Events at 12 weeks. Started Sep 2026; status: recruiting.
02
Drugs
WGc-0201
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07051187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07051187.